Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ZMS
|
|||
| Former ID |
DIB006561
|
|||
| Drug Name |
PK1
|
|||
| Synonyms |
FCE-28068; N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer linked to Gly-Phe-Leu-Gly-doxorubicin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H14Cl2N2O2S
|
|||
| Canonical SMILES |
CC1(C(=O)N(C(=S)N1C)C2=CC(=C(C=C2)Cl)Cl)C3=CC=C(C=C3)O
|
|||
| InChI |
1S/C17H14Cl2N2O2S/c1-17(10-3-6-12(22)7-4-10)15(23)21(16(24)20(17)2)11-5-8-13(18)14(19)9-11/h3-9,22H,1-2H3/t17-/m1/s1
|
|||
| InChIKey |
YPONBLYNQFHCLA-QGZVFWFLSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase II alpha (TOP2A) | Target Info | Modulator | [1] |
| NetPath Pathway | TCR Signaling Pathway | |||
| IL4 Signaling Pathway | ||||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Validated transcriptional targets of deltaNp63 isoforms | |||
| Reactome | G0 and Early G1 | |||
| WikiPathways | Retinoblastoma (RB) in Cancer | |||
| Integrated Pancreatic Cancer Pathway | ||||
| Gastric cancer network 2 | ||||
| Gastric Cancer Network 1 | ||||
| Mitotic G1-G1/S phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009 Jun;34(6):1629-36. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.